Sinovac Biotech Co., Ltd
BiotechBeijing, China, China · Est. 2000
Sinovac Biotech is a Chinese biopharmaceutical company focused on the development and commercialization of vaccines for infectious diseases.
6
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
5
Indications↗
Distinct diseases across all programs
78
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
6 drugs in development
Phase 32
Phase 11
Preclinical1
By Therapeutic Area
top 1
Infectious Disease
686%
R&D Momentum
53/100
Pipeline Velocity
32/100
Trial Completion Rate
98/100
Pipeline Concentration
76/100
Pipeline Freshness
83/100
Activity
Key Events
Jun 27, 2026TrialInactivated Bivalent Enterovirus Vaccine Phase I/II Clinical Trial: Open-Label Observation in Healthy Adults and Children, and Randomized, Double-Blind, Controlled Clinical Trial in Children
Mar 9, 2026TrialStudy to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine
Mar 4, 2026TrialPhase IIIb Clinical Trial to Evaluate Lot-to-lot Consistency of Sinovac Rabies Vaccine
Mar 1, 2026TrialImmunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis Regimen
Mar 1, 2026TrialImmunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen
Jan 6, 2026TrialStudy to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine
Nov 27, 2025TrialPhase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine
Oct 13, 2025TrialInfluenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women
4 more events
Sep 26, 2025TrialPhase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations
Jul 28, 2025TrialImmunogenicity and Safety of Different Dosages of Rabies Vaccine (Serum-free Vero Cell)
Jan 15, 2025TrialTolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell).
Dec 13, 2024TrialEfficacy, Safety, and Immunogenicity of the Bivalent Inactivated Enterovirus Vaccine (Vero Cell)
Details
Company Info
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Therapeutic Focus
vaccinesinfectious diseasespreventive medicine
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Infectious Disease
Infectious Disease
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)